

CAMZYOS[™]
(mavacamten)^{2.5, 5, 10, 15mg}
capsules

Join us to explore long-term data for CAMZYOS[®]

A Review of Interim Data From Ongoing Clinical Studies,
Including the Most Recent Long-Term Outcomes



Mariko Harper,* MD, MS, FACC

Virginia Mason Franciscan Health System

September 29, 2024

12:30 PM ET

Exhibit Hall Theater II

Click [here](#) to
pre-register

*A paid speaker of Bristol Myers Squibb.

This Industry Expert Theater presentation is not part of the scientific program as planned by the HFSA Program Committee. This event is neither sponsored nor endorsed by HFSA. This event does not qualify for continuing education credit. This program is sponsored by Bristol Myers Squibb.

Please see Important Safety Information, including **Boxed WARNING**, and US Full Prescribing Information for CAMZYOS [here](#).



© 2024 MyoKardia, Inc., a Bristol Myers Squibb company.
CAMZYOS[®] and the CAMZYOS Logo are trademarks of MyoKardia, Inc.
3500-US-2400540 08/24